Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Structural heart disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    55 result(s) found for: Structural heart disease. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2015-003146-75 Sponsor Protocol Number: BETA3_LVH Start Date*: 2016-03-14
    Sponsor Name:Université catholique de Louvain (UCL)
    Full Title: A multi-centre randomized, placebo-controlled trial of mirabegron, a new beta3-adrenergic receptor agonist on the progression of left ventricular mass and diastolic function in patients with struct...
    Medical condition: Structural heart disease at high risk for progressive hypertrophic cardiac remodeling at risk of developing HFpEF (heart failure with preserved ejection fraction).
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004849 10019290 Heart insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) PT (Completed) GR (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000376-28 Sponsor Protocol Number: 1245.148 Start Date*: 2018-01-30
    Sponsor Name:Boehringer Ingelheim Limited
    Full Title: A randomised, double-blind, placebo-controlled, mechanistic cardiac magnetic resonance study to investigate the effects of empagliflozin treatment on cardiac physiology and metabolism in patients w...
    Medical condition: Chronic heart failure with reduced (HFrEF) and preserved ejection fraction (HFpEF) diagnosed at least 3 months prior to informed consent.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000885-39 Sponsor Protocol Number: 02289 Start Date*: 2021-01-12
    Sponsor Name:Universitätsmedizin Göttingen
    Full Title: Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure
    Medical condition: Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000134-22 Sponsor Protocol Number: MDCO-CAN-15-01 Start Date*: 2021-01-14
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A Prospective, Open-Label, Single-Arm, Multi-Center Study to Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) AND Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of Thrombosis.
    Medical condition: Postoperative neonatal cardiac subjects who are undergoing surgery for placement of systemic-to pulmonary artery palliative shunts (e.g., Blalock-Taussig or central shunt), right ventricle to pulmo...
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003653-15 Sponsor Protocol Number: AC-055G202 Start Date*: 2017-09-12
    Sponsor Name:ACTELION Pharmaceuticals Ltd
    Full Title: A multi-center, double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of macitentan in subjects with heart failure with preserved ejection fraction and pulmonary vascu...
    Medical condition: Heart failure with preserved ejection fraction and pulmonary vascular disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) DK (Completed) CZ (Completed) AT (Completed) SE (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-021664-16 Sponsor Protocol Number: SVUH Start Date*: 2010-11-04
    Sponsor Name:Solvotrin Innovations Ltd
    Full Title: The role of doxycycline in the management of diastolic dysfunction
    Medical condition: Diastolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10052337 Diastolic dysfunction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2018-001488-21 Sponsor Protocol Number: EST:15/17 Start Date*: 2018-11-06
    Sponsor Name:Sergio Aleman
    Full Title: EFFECT OF VITAMIN D SUPPLEMENTATION ON THE VENTRICULAR DEFORMATION RATE (STRAIN RATE) IN PATIENTS WITH HEART FAILURE WITH PRESERVED OR MODERATELY REDUCED EYECTION FRACTION
    Medical condition: Heart failure with preserved or moderately reduced eyection fraction
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000802-46 Sponsor Protocol Number: D169CC00001 Start Date*: 2018-09-24
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Double-blind, Randomised, Placebo-Controlled Phase IIIb Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failur...
    Medical condition: Heart Failure with Preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) ES (Ongoing) PL (Completed) HU (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-005077-39 Sponsor Protocol Number: BBLOQ-2017 Start Date*: 2018-06-12
    Sponsor Name:Instituto de Investigación Sanitaria INCLIVA
    Full Title: Betablockers Withdrawal in Patients with Heart Failure with Preserved Ejection Fraction and Chronotropic Incompetence: Effect on Functional Capacity and life quality
    Medical condition: Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10019280 Heart failures HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004072-59 Sponsor Protocol Number: 1245-0167 Start Date*: 2018-04-03
    Sponsor Name:Boehringer-Ingelheim España, S.A.
    Full Title: A phase III randomised, double-blind trial to evaluate the effect of 12 weeks treatment of once daily EMPagliflozin 10 mg compared with placebo on ExeRcise ability and heart failure symptoms, In pa...
    Medical condition: Chronic Heart Failure with preserved Ejection Fraction (HFpEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) PT (Completed) PL (Completed) SE (Completed) NO (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001747-31 Sponsor Protocol Number: CLCZ696D2301 Start Date*: 2013-09-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure pat...
    Medical condition: Heart failure with preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10069211 Diastolic heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) AT (Completed) BG (Completed) DE (Prematurely Ended) ES (Completed) NO (Completed) GB (Completed) NL (Completed) CZ (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) FI (Completed) HR (Completed) PL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2006-000946-38 Sponsor Protocol Number: EFC5314 Start Date*: 2007-01-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: International randomized double blind clinical study evaluating the efficacy and safety of clopidogrel 0.2mg/kg once daily versus placebo in neonates and infants with cyanotic congenital heart dise...
    Medical condition: Neonates or infants (age less than or equal to 92 days at the time of randomization) with systemic to pulmonary arterial shunt for palliation of cyanotic congenital heart disease.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019273 Heart disease congenital LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) FI (Completed) SE (Completed) DK (Completed) PT (Completed) FR (Completed) HU (Completed) IT (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-019713-21 Sponsor Protocol Number: CS/2007/2678 Start Date*: 2010-06-17
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A RANDOMISED CONTROLLED TRIAL TO COMPARE NORMOXIC VERSUS STANDARD CARDIOPULMONARY BYPASS IN CYANOTIC CHILDREN UNDERGOING CARDIAC SURGERY
    Medical condition: The study investigates reoxygenation injury in cyanotic paediatric patients undergoing on-pump cardiac surgery. The types of heart condition being investigated result in chronic low blood oxygen sa...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010395 Congenital cardiac malpositions and transpositions HLT
    12.1 10010397 Congenital cardiac structural defects NEC HLT
    12.1 10010396 Congenital cardiac septal defect NOS LLT
    12.1 10062326 Congenital cardiac septal defect LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-005302-26 Sponsor Protocol Number: DW.0701.005.2020P Start Date*: 2023-01-05
    Sponsor Name:John Paul II Hospital
    Full Title: The effect of sacubitril/valsartan versus ramipril on left ventricular function and remodeling in patients with ischemic heart failure with mid-range ejection fraction
    Medical condition: heart failure with moderately reduced ejection fraction (HFmrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000752-18 Sponsor Protocol Number: 17-924 Start Date*: 2019-02-19
    Sponsor Name:UMC Utrecht
    Full Title: Ajmaline provocation in asymptomatic PLN and PKP2 mutation carriers for early detection of Arrhythmogenic Cardiomyopathy
    Medical condition: Arrhythmogenic cardiomyopathie due to PLN or PKP2 mutations, asymptomatic family members who are carriers of PLN or PKp2 mutations, patients without structural heart disease who are referred for aj...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003688-37 Sponsor Protocol Number: KKS-243 Start Date*: 2018-07-06
    Sponsor Name:Philipps-Universität Marburg
    Full Title: Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION), A randomized, placebo-controll...
    Medical condition: Combined post- and pre-capillary pulmonary hypertension and heart failure with preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077732 Pulmonary hypertension WHO functional class II LLT
    20.0 100000004849 10024106 Left heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002278-11 Sponsor Protocol Number: 1245.110 Start Date*: 2017-06-19
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Frac...
    Medical condition: Heart failure (HF) with preserved ejection fraction (EF).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) NL (Completed) ES (Completed) BE (Completed) GB (GB - no longer in EU/EEA) LT (Prematurely Ended) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-004629-18 Sponsor Protocol Number: helmich-veni-2019 Start Date*: 2017-04-13
    Sponsor Name:Radboud University Nijmegen
    Full Title: The noradrenergic basis of Parkinson’s tremor: a systems-level fMRI approach
    Medical condition: Tremor in Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-002895-42 Sponsor Protocol Number: D6580C00003 Start Date*: 2018-11-22
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double blind, placebo-controlled, parallel group, multicentre, phase 2a study to assess target engagement, safety and tolerability of AZD4831 in patients with Heart Failure with prese...
    Medical condition: Heart failure with preserved Ejection Fraction (HFpEF) and heart failure with mid-range Ejection Fraction (HFmrEF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) FI (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004277-41 Sponsor Protocol Number: 16.0012 Start Date*: 2017-01-18
    Sponsor Name:St George's University of London
    Full Title: An observational study into the variety of electrocardiographic responses to an ajmaline Provocation in healthy subjects. What are the genetic and structural variations dictating this response ?
    Medical condition: Study in the healthy population. This is a study of a test used in the diagnosis of the condition, Brugada Syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003109 Arrest cardiac LLT
    20.0 10007541 - Cardiac disorders 10003119 Arrhythmia PT
    20.0 10007541 - Cardiac disorders 10059027 Brugada syndrome PT
    20.1 100000004867 10042436 Sudden death unexplained LLT
    21.0 100000004848 10069779 Brugada-type ECG LLT
    20.0 100000004848 10008396 Change in ECG LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:19:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA